Purification and Zakat (for long-term investing) calculations are in USD per share and based on AAOIFI methodology. AAOIFI requires purification every financial period (e.g. quarterly).
If you follow S&P Shariah’s Dividend-only purification, then remove the impure income % from the dividends you receive. No purification required for non-dividend paying stocks, according to S&P Shariah.
For Zakat, if you did not invest in a company from a long term perspective, then consider the shares as trading goods and give 2.5% of the total value if a year has passed on them.
Company Profile
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the formulation, development, and commercialization of therapies for diseases and conditions of the eye. Its first commercial drug product, DEXTENZA, is developed for the treatment of ocular inflammation and pain ophthalmic surgery and ocular itching associated with allergic conjunctivitis. Its earlier stage development assets include: axitinib intravitreal implant (OTX-TKI), is under Phase I clinical trials for the treatment of wet age-related macular degeneration (AMD) and diabetic retinopathy; travoprost intracameral implant (OTX-TIC), is under Phase II clinical trial for the treatment of primary open-angle glaucoma or ocular hypertension; and dexamethasone intracanalicular insert (OTX-DED), for the short-term treatment of the signs and symptoms of dry eye disease; and cyclosporine intracanalicular insert (OTX-CSI), for the chronic treatment of dry eye disease, both of which have completed Phase II clinical trials.
OCUL - Ocular Therapeutix Inc
Report
There was a problem reporting this post.
Block Member?
Please confirm you want to block this member.
You will no longer be able to:
See blocked member's posts
Mention this member in posts
Please allow a few minutes for this process to complete.